DOI : 10.17577/Abstract
The expansion of digital pharmacy services has made it possible for patients to obtain healthcare information, complete clinical assessments and access appropriate treatment without every interaction requiring a face-to-face consultation. These systems can be particularly valuable for sensitive health concerns, where privacy concerns or embarrassment may otherwise discourage patients from seeking professional advice. However, digital pharmacy platforms necessarily process information relating to identity, medical history, current medication and potentially highly sensitive conditions. Protecting this information therefore requires more than adding security controls after a platform has been developed. This paper examines a privacy-by-design approach to digital pharmacy architecture, focusing on authentication, data minimisation, encrypted data transmission and storage, secure clinical questionnaires, access control, auditability and medication fulfilment. Erectile dysfunction is considered as a practical case study demonstrating why privacy protections must operate alongside clinical safety controls. The paper argues that digital pharmacy platforms should treat privacy, cybersecurity and clinical governance as interconnected system requirements rather than independent features.
Keywords: digital pharmacy, privacy by design, healthcare cybersecurity, telepharmacy, patient data, authentication, encryption, digital health
I. Introduction
Digital healthcare systems increasingly move activities that once required direct physical interaction into online environments.
In a digital pharmacy pathway, a patient may create an account, provide identity information, describe symptoms, disclose existing medical conditions, list current medicines, complete a clinical assessment, communicate with a healthcare professional and arrange delivery of an appropriate medicine.
This creates significant opportunities for convenience and accessibility, but it also creates an unusually sensitive data environment.
Healthcare information can reveal far more than a conventional ecommerce transaction. A pharmacy platform may process information about sexual health, reproductive health, mental wellbeing, weight, hair loss, infections, cardiovascular conditions and medication history.
For patients seeking treatment for conditions they consider private or embarrassing, the confidentiality of this information may influence whether they engage with healthcare at all.
Privacy therefore needs to be treated as a core architectural requirement.
The concept of data protection by design requires organisations to consider privacy at the initial design stage of a system and throughout its lifecycle rather than attempting to add safeguards after deployment. Current UK Information Commissioner’s Office guidance similarly emphasises that appropriate technical and organisational measures should be integrated into processing activities from the outset.
For digital pharmacy systems, this principle has implications for everything from database architecture to interface design.
II. A Privacy-Oriented Digital Pharmacy Architecture
A simplified digital pharmacy system can be viewed as several interacting layers:
- user identity and authentication;
- patient-facing application;
- clinical assessment and decision support;
- healthcare professional interface;
- medication and fulfilment systems;
- data storage;
- communications infrastructure; and
- audit, security and monitoring services.
Security weaknesses at any one of these layers can undermine the privacy of the entire service.
A highly encrypted database, for example, offers limited protection if an attacker can easily compromise a patient account. Strong authentication alone is insufficient if internal users are able to access records unrelated to their role.
Privacy-by-design therefore requires defence in depth.
Instead of asking whether patient data is “secure”, engineers should ask who can access each data element, why they need it, how long it must be retained, where it is transmitted, how access is authenticated and how inappropriate activity can be detected.
III. Data Minimisation at the Point of Collection
One of the simplest methods of reducing privacy risk is to avoid collecting unnecessary information.
Digital clinical questionnaires can easily expand because adding another field has little apparent technical cost.
From a privacy perspective, however, every additional data point creates another item that must be stored, protected, governed and potentially disclosed if a security incident occurs.
A privacy-oriented system should therefore separate information that is clinically necessary from information that is merely convenient to collect.
For example, a questionnaire evaluating suitability for a medicine may legitimately require information about certain health conditions or current medications. It does not follow that every part of a patient’s broader medical history needs to be collected.
The same principle applies to analytics.
Data originally supplied for a clinical assessment should not automatically become general behavioural or marketing data simply because it is technically available.
The UK’s data-protection-by-default framework explicitly links privacy-by-design with principles including purpose limitation and data minimisation, requiring organisations to limit processing to information necessary for the defined purpose.
From an engineering perspective, this suggests that data minimisation should be encoded within the system’s data model rather than relying solely on organisational policy.
IV. Authentication Without Creating Excessive Friction
Authentication presents an important design trade-off.
A platform containing sensitive medical information requires strong protection against account takeover. At the same time, excessively complicated authentication processes may discourage legitimate users from completing a consultation.
Modern digital identity standards increasingly approach authentication through risk and assurance levels rather than treating every online interaction identically.
NIST’s current Digital Identity Guidelines, revised in 2025, provide technical frameworks covering identity proofing, enrolment, authentication and federation and distinguish between different levels of authentication assurance.
A digital pharmacy platform should similarly apply authentication controls proportionately.
Accessing general educational information may require no authentication.
Viewing a personal treatment history clearly requires substantially stronger assurance.
Changing account credentials, accessing stored clinical information or modifying delivery information may justify additional verification.
Multi-factor authentication, secure account-recovery processes, session management and monitoring for unusual login behaviour can therefore form part of a layered approach.
Account recovery is especially important.
There is little value in implementing strong authentication if the recovery mechanism allows an attacker to bypass it with minimal information.
V. Encryption of Data in Transit and at Rest
Digital pharmacy platforms routinely move information between browsers, application servers, clinical interfaces, databases and external services.
Sensitive information should therefore be protected both while being transmitted and while stored.
Encryption in transit reduces the risk of information being intercepted as it moves between systems.
Encryption at rest reduces exposure if storage infrastructure or backups are accessed without authorisation.
However, encryption should not be treated as an isolated checkbox.
Key management, rotation, storage architecture and access privileges all influence how effective an encryption strategy actually is.
Research published within IJERT’s own healthcare-security literature has repeatedly identified confidentiality, authentication and protection of cloud-hosted patient data as important challenges for electronic healthcare systems.
Modern platforms should extend this thinking beyond the central database.
Logs, backups, document storage, cached information, analytics pipelines and messaging systems can all contain health-related information.
Protecting only the principal patient database leaves significant secondary exposure.
VI. Designing Secure Clinical Questionnaires
The clinical questionnaire is one of the most important components of an online pharmacy.
From the user’s perspective, it may appear to be a sequence of relatively simple questions.
Architecturally, however, it performs several functions simultaneously.
It gathers health information, structures data for clinical review, supports treatment-suitability decisions and potentially identifies patients who require escalation to another healthcare service.
Secure questionnaire design therefore involves both information security and clinical safety.
Answers should be transmitted securely and associated with the correct authenticated patient.
Previous answers should not be exposed through insecure browser storage or predictable URLs.
Administrative users should not automatically receive access to clinically sensitive responses simply because they work within the same organisation.
Questionnaire logic also needs careful control.
If branching rules determine whether additional safety questions appear, changes to those rules should be tested, version-controlled and auditable.
A software defect affecting questionnaire logic can become a clinical risk even when the cybersecurity of the application itself remains intact.
VII. Role-Based Access and the Principle of Least Privilege
Not every user within a digital pharmacy requires the same information.
A pharmacist conducting a clinical assessment may legitimately need access to medical responses and medication history.
A member of staff responsible only for dispatch may need an address and fulfilment information but not the complete clinical questionnaire.
A customer-support employee may require still another level of access.
This makes role-based access control particularly important.
Systems should apply the principle of least privilege, giving users access to the minimum information and functionality required for their role.
Permissions should also be reviewed when responsibilities change.
An employee moving from a clinical role to a non-clinical role should not retain historical permissions simply because an account already exists.
Privileged access should additionally be logged.
Audit records can provide visibility into which account accessed a patient record, when access occurred and what actions were performed.
This helps support both security investigations and organisational accountability.
VIII. Sensitive Men’s Health as a Privacy and Safety Case Study
Erectile dysfunction illustrates why digital pharmacy privacy cannot be separated from clinical governance.
Some men may prefer to begin a consultation digitally because discussing sexual function face-to-face feels uncomfortable.
A well-designed platform can reduce that initial communication barrier by allowing the patient to provide relevant information privately and systematically.
However, the resulting information is highly sensitive.
The system may process details concerning sexual function alongside cardiovascular history, medications and other health factors.
At the same time, privacy cannot be used to justify reducing the quality of the clinical assessment.
For example, sildenafil, the active ingredient in Viagra, is an established treatment for erectile dysfunction in suitable adult men. Its prescribing information states that sexual stimulation is required for efficacy and identifies important contraindications, including co-administration with nitrate medicines because of the risk of significant hypotension.
A digital pathway assessing suitability therefore needs to collect enough information to identify relevant contraindications while avoiding unnecessary collection of unrelated personal data.
This illustrates the central design problem.
Collect too little data and clinical safety may be weakened.
Collect too much and privacy exposure increases unnecessarily.
Privacy-by-design aims to identify the minimum dataset capable of supporting the required clinical decision safely.
IX. Separating Clinical Data From Fulfilment Data
Medication fulfilment introduces another opportunity for data minimisation.
Once a clinical decision has been made, the logistical system responsible for preparing and dispatching an order does not necessarily require access to the full consultation record.
System architecture can therefore separate clinical and fulfilment domains.
A clinical service may record the assessment and treatment decision, while the fulfilment layer receives only the information necessary to supply the authorised medicine to the correct patient.
Appropriate separation can reduce the number of systems and users exposed to sensitive medical histories.
The same principle can extend to third-party service providers.
A delivery provider may need a recipient name and address. It generally does not require the patient’s clinical questionnaire.
A payment processor requires information necessary to complete a payment, but should not automatically receive detailed medical information.
Good system architecture prevents unnecessary information sharing by design rather than relying on every downstream user to ignore data they do not need.
X. Auditability and Monitoring
Privacy controls are more effective when their operation can be verified.
Digital pharmacy platforms should therefore maintain appropriately protected audit records for important events such as:
● authentication attempts;
● changes to account credentials;
● access to clinical records;
● modifications to clinical decisions;
● changes to system permissions; and
● relevant administrative actions.
Audit logs themselves must be protected because they may contain sensitive metadata.
Monitoring can also help identify anomalous behaviour.
A clinical account accessing an unusually large number of unrelated patient records, for example, may warrant investigation even if valid credentials were used.
This demonstrates why privacy engineering extends beyond preventing external cyberattacks.
Insider misuse, excessive privileges, configuration errors and accidental disclosure can also compromise confidentiality.
XI. Privacy-Friendly Interface Design
Privacy is also affected by what appears on the screen.
A technically secure application can still expose sensitive information through poor interface decisions.
Medication names appearing prominently in push notifications, emails or lock-screen notifications may reveal a condition to another person who has access to the device.
Similarly, email subject lines should not disclose unnecessary clinical details.
Session timeouts can reduce exposure on shared devices, while clear sign-out controls help users actively end access.
Interfaces should also explain why sensitive information is being requested.
Users are more likely to understand a clinical questionnaire when the connection between the question and the healthcare decision is clear.
Trust therefore depends partly on transparency.
Privacy-by-design is not simply a cybersecurity principle; it is also a user-experience principle.
XII. Secure Development and Lifecycle Management
A digital pharmacy platform continues to change after launch.
New medicines are introduced, questionnaire logic changes, third-party services are replaced and software dependencies are updated.
Privacy engineering must therefore continue throughout the development lifecycle.
Threat modelling can identify foreseeable attack paths before new functionality is deployed.
Code review, dependency management, vulnerability testing and penetration testing can identify technical weaknesses.
Access rights should be reviewed periodically, while obsolete data and inactive accounts should be handled according to defined retention policies.
Major architectural changes should trigger a reassessment of privacy risks rather than inheriting assumptions from the original system.
This lifecycle approach reflects the central privacy-by-design principle: protection should remain part of the system throughout its operation rather than being treated as a one-time compliance exercise.
XIII. Conclusion
Digital pharmacy platforms occupy an unusual position between healthcare systems and consumer-facing digital services.
They need the usability expected from modern online platforms while simultaneously protecting medical information and supporting safe clinical decision-making.
For sensitive health conditions, the quality of privacy design may have an additional consequence: it can influence whether a patient feels comfortable engaging with healthcare in the first place.
Effective privacy-by-design therefore requires multiple controls working together.
Authentication protects access to patient accounts. Encryption protects information in storage and transmission. Data minimisation limits unnecessary exposure. Role-based permissions restrict internal access. Secure questionnaires support structured clinical decisions. System separation prevents fulfilment and third-party services from receiving information they do not require. Auditability provides accountability when something goes wrong.
Most importantly, privacy and clinical safety should not be designed independently.
The objective is not to collect as little information as technologically possible. It is to identify and securely process the minimum information necessary to provide an appropriate healthcare service.
Digital pharmacy systems that achieve this balance are more likely to provide both the convenience patients expect and the confidentiality that sensitive healthcare requires.
References
[1] Information Commissioner’s Office, Data Protection by Design and by Default, updated February 2026.
[2] D. Temoshok, J. Fenton, Y. Choong, N. Lefkovitz, A. Regenscheid, R. Galluzzo and J. Richer, Digital Identity Guidelines: Authentication and Authenticator Management, NIST Special Publication 800-63B-4, National Institute of Standards and Technology, 2025. doi:10.6028/NIST.SP.800-63B-4.
[3] D. Temoshok et al., Digital Identity Guidelines, NIST Special Publication 800-63-4, National Institute of Standards and Technology, 2025. doi:10.6028/NIST.SP.800-63-4.
[4] A. B. S. Kumar, A. N., E. K. Jacob, A. Binu and D. S. B., “Enhanced Data Security in Cloud-based E-Health Care System,” International Journal of Engineering Research & Technology, 2022.
[5] A. G. M. et al., “Cloud Based Health Care Data Privacy System Using Hybrid Techniques,” International Journal of Engineering Research & Technology, vol. 11, no. 5, 2023.
[6] K. G. and B. S. G., “Secure Sharing of Patient’s Sensitive Information using Cloud Computing,” International Journal of Engineering Research & Technology, 2018.
